<DOC>
	<DOCNO>NCT02083666</DOCNO>
	<brief_summary>The main purpose study assess safety tolerability SOBI002 healthy volunteer follow single repeat administration .</brief_summary>
	<brief_title>Safety Tolerability SOBI002 Healthy Volunteers Following Single Repeated Administration</brief_title>
	<detailed_description>This double-blind , placebo-controlled , randomize within dose cohort single repeat dose study sequential dose escalation . Eligible volunteer divide dose cohort cohort , new panel 8 volunteer randomize receive either SOBI002 ( n=6 ) placebo ( n=2 ) . SOBI002 either administer subcutaneously intravenously .</detailed_description>
	<criteria>Females nonchildbearing potential male 18 45 year age Judged Principal Investigator healthy basis medical history prestudy physical examination include 12lead electrocardiogram ( ECG ) , 24hour Holter ECG , vital sign blood urine laboratory assessment . Females childbearing potential Clinically significant disease Clinically significant abnormal laboratory , ECG , vital sign safety finding determine medical history , physical examination evaluation conduct screen admission .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Dose cohort</keyword>
	<keyword>Escalating dose</keyword>
	<keyword>Single dose</keyword>
	<keyword>Multiple dose</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>volunteer</keyword>
</DOC>